Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in NTLA.
← Back to Free Index

NTLA

Analysis as of: 2026-02-20
Intellia Therapeutics, Inc.
Clinical-stage biotech developing in vivo and ex vivo CRISPR/Cas9 gene-editing therapies, led by lonvo-z (HAE) and nex-z (ATTR).
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

One-time HAE therapy is the 2031 value engine
The 5-year outcome is primarily a lonvo-z launch and access-execution story; success can re-rate the business from “platform discount” to rare-disease franchise. Nex-z adds convex upside, but remains gated by safety-led regulatory permissioning.

Analysis

Thesis
If lonvo-z becomes the first broadly adopted one-time prophylaxis in HAE, NTLA can convert today’s “platform discount” into a repeatable rare-disease launch engine (payer contracting + site workflow + real-world data), while nex-z restart progress keeps a second, non-linear upside option alive despite ongoing regulatory gating.
Last Economy Alignment
AI cheapens discovery and trial ops, but value still hinges on scarce gates: regulatory trust, safety proof, and proprietary clinical datasets that compound learnings.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
9.1x (from 5 most recent analyses)
Reasoning
NTLA’s upside is a de-risking ladder: (1) lonvo-z Phase 3 readout, (2) filing/approval, (3) a launch that solves reimbursement friction for a one-time therapy. If they execute the “access + verification” playbook (outcomes-linked contracts, fast coverage decisions, certified care pathways, registry-grade real-world evidence), the company can scale a rare-disease franchise and regain a higher-quality multiple versus today’s safety/regulatory discount. Nex-z contributes mainly as option value unless the ATTR-CM hold clears cleanly.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The binding risk is regulatory permissioning after liver safety events (especially for nex-z), which can delay or narrow value capture. Next is commercialization friction for one-time therapies (coverage mechanics, outcomes verification, site capacity/monitoring). Finally, extended timelines raise financing and dilution risk, which can cap equity compounding even if clinical progress is real.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.19
They control scarce clinical-grade gene-editing datasets and the know-how to run regulator-satisfying workflows, which AI can’t shortcut. The threat is regulatory permissioning after safety events—if trust breaks, progress and financing both stall.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$22.95
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case